Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2016

Filed with the SEC on Mar 8, 2016 and accepted by EDGAR at Mar 8, 2016, 17:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-11-01 to 2016-01-31$0us-gaap:Revenues
Revenue9 months2015-05-01 to 2016-01-31$0us-gaap:Revenues
Cost of revenue3 months2015-11-01 to 2016-01-31$0us-gaap:CostOfRevenue
Cost of revenue9 months2015-05-01 to 2016-01-31$0us-gaap:CostOfRevenue
Gross profit3 months2015-11-01 to 2016-01-31$0us-gaap:GrossProfit
Gross profit9 months2015-05-01 to 2016-01-31$0us-gaap:GrossProfit
Research and development3 months2015-11-01 to 2016-01-31$574.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2015-05-01 to 2016-01-31$1.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-11-01 to 2016-01-31−$1.8mus-gaap:OperatingIncomeLoss
Operating income9 months2015-05-01 to 2016-01-31−$4.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2015-11-01 to 2016-01-31$126us-gaap:InterestExpense
Interest expense9 months2015-05-01 to 2016-01-31$952us-gaap:InterestExpense
Income tax3 months2015-11-01 to 2016-01-31$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2015-05-01 to 2016-01-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2015-11-01 to 2016-01-31−$1.8mus-gaap:NetIncomeLoss
Net income9 months2015-05-01 to 2016-01-31−$4.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2015-11-01 to 2016-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2015-05-01 to 2016-01-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2015-05-01 to 2016-01-31−$3.1mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2016-01-31$2.9mus-gaap:Cash
Current assetsAt period end2016-01-31$2.9mus-gaap:AssetsCurrent
Total assetsAt period end2016-01-31$8.0mus-gaap:Assets
Current liabilitiesAt period end2016-01-31$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-01-31$1.1mus-gaap:Liabilities
Shareholders' equityAt period end2016-01-31$6.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-16-005399. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.